Picture this: You’ve completed your Phase Ib oncology trial and your results show a positive signal. Now you need to ensure that clinical endpoints will be met with a high proportion of responders in your next trial. Profiling cancer patients for treatment has long taken a single-gene approach. We’ve developed a novel method using multi-omic signatures to provide higher predictability of drug response. Why a network biology approach is key in defining the right target subgroups: ✅Omic signatures provide better patient classification performance ✅Interactomes have a higher correlation with drug response ✅Omic signatures are often related to progression pathways, therefore causal in nature 👉Download our white paper Predicting Response Patterns to AKT Inhibitor MK2206 in Breast Cancer Patients: How Next-Order Signatures can Identify Patient Profiles: https://lnkd.in/eCze3Xde Authors: Nick Chahley, Ariss ALIMI, Armstrong Murira and Nardin Nakhla
Simmunome Inc.’s Post
More Relevant Posts
-
𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗦𝗻𝗶𝗽 𝟮.𝟲𝟵: This study investigates the use of #DNA #tetrahedron, a highly programmable #nanocage, for delivering #doxorubicin, a #chemotherapy drug, to treat metastatic breast cancer. The DNA tetrahedron offers advantages like #biocompatibility and #stability, making it a safe and effective drug carrier. Results show that doxorubicin-loaded DNA tetrahedrons inhibit #cancer cell migration and invasion in both 2D and 3D experimental models, highlighting their potential as a promising therapeutic approach for metastatic breast cancer. Read the full paper here: https://lnkd.in/dW-Fqz-v #IITGNResearchSnips #Research #IITGNResearchers
-
-
Where, how and why can complex issues like circulating tumor DNA, and by extension, minimal residual disease help us to drive novel trial designs that are more patient friendly and concurrently can expedite the safety and efficacy evaluations of novel therapeutics? In this episode of the Syneos Health Podcast, Chief Scientific Officer Nick Kenny is joined by oncology experts Warl Harb and Patrick Kelly to discuss how circulating tumor DNA (ctDNA) is transforming cancer treatment and clinical trial design, and its potential to drive more patient-centric, adaptive clinical trials. Listen to the full episode: https://ow.ly/lOTl30sHL38
-
-
Where, how and why can complex issues like circulating tumor DNA, and by extension, minimal residual disease help us to drive novel trial designs that are more patient friendly and concurrently can expedite the safety and efficacy evaluations of novel therapeutics? In this episode of the Syneos Health Podcast, Chief Scientific Officer Nick Kenny is joined by oncology experts Warl Harb and Patrick Kelly to discuss how circulating tumor DNA (ctDNA) is transforming cancer treatment and clinical trial design, and its potential to drive more patient-centric, adaptive clinical trials. Listen to the full episode: https://ow.ly/cgS730sHl2M
-
-
This is an important demonstration of the capabilities of the Veracyte Diagnostic Platform, how a community of investigators can apply this platform to critical research, how valuable clinical management insights can be extracted all while serving the needs of our patients.
Veracyte today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at the upcoming 2024 AUA Annual Meeting. The studies include those that evaluate the clinical utility of our Decipher tests in guiding treatment decisions for patients with prostate or bladder cancer. Additionally, other presentations will share new insights into the underlying biology of these cancers, which were derived through use of Veracyte’s Decipher GRID research tool. Learn more: https://lnkd.in/gpGzdk7e #AUA2024 #ProstateCancer #BladderCancer
-
In business news, BeiGene has proposed a name change to BeOne Medicines. The new logo is clever. As per their explanation: The word “Onc” spelled in red within “One” illustrates our redoubled commitment to oncology; and The power button within the last “e” represents our always “on” approach in pursuing novel medicines that turn cancer “off” by disrupting key drivers of cancer cell growth and survival, harnessing the body’s immune system to attack tumors, and targeting specific biomarkers of cancer. The tilted angle of the button embodies our path which is not always straight-forward as we push the boundaries of science. https://lnkd.in/eDsUDdXy
-
-
🎥 Good news! Our latest webinar is now available to watch on demand! In it, you'll learn all about the latest advancements in organ-on-a-chip for cancer research and drug discovery. This webinar will not only cover capturing the tumor microenvironment (TME) in hepatocellular carcinoma in vitro but will explore how MIMETAS can help put therapeutic targets in immuno-oncology into patient context. In this webinar, you will: - Gain unparalleled insights into replicating TME dynamics in vitro. - Engage in meaningful dialogue about TME complexities, focusing on angiogenesis, stroma, and immune responses. - Understand the impact of TME variables on the success of existing treatments. - Discover how partnership with MIMETAS can impact your oncology research, speeding up discovery and improving therapy prediction accuracy. Watch the webinar here: https://lnkd.in/eBpNv8YE #CancerResearch #Immunooncology #OncologyResearch
Webinar | Phenotypic Disease Modeling for Immuno-Oncology: Putting Targets into Patient Context
register.gotowebinar.com
-
Monovalent PI3Ka Degrader, Inavolisib, Approved in Breast Cancer! CONGRATS to everyone at Genentech (current & former) involved on the PI3Ka degradation program on today's approval for advanced breast cancer - such an incredible scientific story and hopefully a powerful new treatment option for many patients: https://lnkd.in/gMShNtwt PI3K has been an extensively studied oncology target with over 2 million cancer patients estimated annually with mutations in PIK3CA, the gene encoding the p110a subunit of PI3Ka. However, identifying oral compounds with selectivity against PI3Ka vs. other isoforms has been challenging, and inhibition of WT PI3Ka can come with undesired side effects. Inavolisib is not only highly selective against other PI3K isoforms (>300-fold over delta) and appears to be functionally selective against mutant p110a through an unexpected protein degradation mechanism that was discovered at Genentech. This molecule was nominated as one of the 2021 Molecule of the Year candidates on Drug Hunter: https://lnkd.in/ghUqjRrH You can read more about inavolisib, its unique mechanism, how it differentiates, and where it came from in this profile: https://lnkd.in/gRuEVk7k Congrats Emily Hanan, Marie-Gabrielle Braun, Steve Staben, Ciara Metcalfe, Timothy Heffron, Anwesha Dey, Lori Friedman, and countless others on the generations of PI3K molecules that led to this approval.
inavolisib
drughunter.com
-
Have you registered for our upcoming webinar? This Tuesday, March 26, Henriette Lanz, PhD, MIMETAS' Vice President of Biology, will be presenting the latest advancements in organ-on-a-chip for cancer research and drug discovery. This webinar will not only cover capturing the tumor microenvironment (TME) in hepatocellular carcinoma in vitro but will explore how MIMETAS can help put therapeutic targets in immuno-oncology into patient context. 🔬 Why Attend? - Gain unparalleled insights into replicating TME dynamics in vitro. - Engage in meaningful dialogue about TME complexities, focusing on angiogenesis, stroma, and immune responses. - Understand the impact of TME variables on the success of existing treatments. - Discover how partnership with MIMETAS can impact your oncology research, speeding up discovery and improving therapy prediction accuracy. Don’t miss out! Secure your spot now: https://lnkd.in/dGXBjJsx #PhenotypicModeling #CancerResearch #ImmunoOncology #oncologyresearch #DrugDiscovery
Webinar | Phenotypic Disease Modeling for Immuno-Oncology: Putting Targets into Patient Context
register.gotowebinar.com
-
Where, how and why can complex issues like circulating tumor DNA, and by extension, minimal residual disease help us to drive novel trial designs that are more patient friendly and concurrently can expedite the safety and efficacy evaluations of novel therapeutics? In this episode of the Syneos Health Podcast, Chief Scientific Officer Nick K. is joined by oncology experts Wael Harb, MD, MBA and Patrick Kelly to discuss how circulating tumor DNA (ctDNA) is transforming cancer treatment and clinical trial design, and its potential to drive more patient-centric, adaptive clinical trials. Listen to the full episode: https://lnkd.in/eE95dgJP #SyneosHealth
-
-
"Hot off the press! 📰 This collaborative study on ctDNA levels across cancer types and stages conducted by various ctDNA assay manufacturers with Friends of Cancer Research is impressive! As expected, late-stage cancers show promising consistency in baseline ctDNA levels, supporting its potential as a robust clinical biomarker. However, the variability in early-stage NSCLC emphasizes the need for standardized data and assay protocols. Exciting times for precision oncology! 🔬💉 #CancerResearch #PrecisionMedicine Read more about it here: https://lnkd.in/g3iTaHcm
Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages
mdpi.com
